Discovery and identification of potential biomarkers of papillary thyroid carcinoma

Molecular Cancer

Volumn 8, Issue , 2009, Pages 79-

  Fan, Yuxia ^a   Shi, Linan ^b   Liu, Qiuliang ^a   Dong, Rui ^a   Zhang, Qian ^a   Yang, Shaobo ^a   Fan, Yingzhong ^a   Yang, Heying ^a   Wu, Peng ^b   Yu, Jiekai ^c   Zheng, Shu ^c   Yang, Fuquan ^b   Wang, Jiaxiang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b INSTITUTE OF BIOPHYSICS   (China)

^c THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN C1; APOLIPOPROTEIN C3; BIOLOGICAL MARKER; HAPTOGLOBIN ALPHA 1 CHAIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; MALE; MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SUPPORT VECTOR MACHINE; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; THYROID PAPILLARY CARCINOMA; UPREGULATION;

APOLIPOPROTEIN C-I; APOLIPOPROTEIN C-III; CARCINOMA, PAPILLARY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HAPTOGLOBINS; HUMANS; IMMUNOASSAY; MOLECULAR WEIGHT; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 70449336932     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-8-79     Document Type: Article

References (33)

1. Ronckers CM, McCarron P, Ron E. Thyroid cancer and multiple primary tumors in the SEER cancer registries. Int J Cancer 2005, 117:281-288. 10.1002/ijc.21064, 15880372.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96. 10.3322/CA.2007.0010, 18287387.
3. Pelizzo MR, Merante Boschin I, Toniato A, Casal Ide E, Mian C, Rubello D, Pagetta C. Diagnosis, treatment, prognostic factors and long-term outcome in papillary thyroid carcinoma. Minerva Endocrinol 2008, 33:359-379.
4. Hayashi N, Kitaoka M. Fine-needle aspiration biopsy of the thyroid nodule: uses and limitations. Nippon Rinsho 2007, 65:2003-2007.
5. Inohara H, Segawa T, Miyauchi A, Yoshii T, Nakahara S, Raz A, Maeda M, Miyoshi E, Kinoshita N, Yoshida H, Furukawa M, Takenaka Y, Takamura Y, Ito Y, Taniguchi N. Cytoplasmic and serum galectin-3 in diagnosis of thyroid malignancies. Biochem Biophys Res Commun 2008, 376:605-610. 10.1016/j.bbrc.2008.09.041, 18809382.
6. Saussez S, Glinoer D, Chantrain G, Pattou F, Carnaille B, Andre S, Gabius HJ, Laurent G. Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease. Thyroid 2008, 18:705-712. 10.1089/thy.2007.0361, 18630998.
7. Asa SL. The role of immunohistochemical markers in the diagnosis of follicular-patterned lesions of the thyroid. Endocr Pathol 2005, 16:295-309. 10.1385/EP:16:4:295, 16627917.
8. Nygaard B, Frisch T, Kiss K. Thyroid papillary cancer using TPO staining. Ugeskr Laeger 2008, 170:1571.
9. Park YJ, Kwak SH, Kim DC, Kim H, Choe G, Park J, Jang HC, Park SH, Cho BY, Park SY. Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules. J Korean Med Sci 2007, 22:621-628. 10.3346/jkms.2007.22.4.621, 2693809, 17728499.
10. Maurya P, Meleady P, Dowling P, Clynes M. Proteomic approaches for serum biomarker discovery in cancer. Anticancer Res 2007, 27:1247-1255.
11. Tomosugi N. Discovery of disease biomarkers by ProteinChip system; clinical proteomics as noninvasive diagnostic tool. Rinsho Byori 2004, 52:973-979.
12. Luo J, Qian JH, Yu JK, Zheng S, Xie X, Lu WG. Discovery of altered protein profiles in epithelial ovarian carcinogenesis by SELDI mass spectrometry. Eur J Gynaecol Oncol 2008, 29:233-238.
13. Wang J, Zhang X, Ge X, Guo H, Xiong G, Zhu Y. Proteomic studies of early-stage and advanced ovarian cancer patients. Gynecol Oncol 2008, 111:111-119. 10.1016/j.ygyno.2008.06.031, 18703221.
14. Skytt A, Thysell E, Stattin P, Stenman UH, Antti H, Wikstrom P. SELDI-TOF MS versus prostate specific antigen analysis of prospective plasma samples in a nested case-control study of prostate cancer. Int J Cancer 2007, 121:615-620. 10.1002/ijc.22722, 17410539.
15. Liu D, Cao L, Yu J, Que R, Jiang W, Zhou Y, Zhu L. Diagnosis of Pancreatic Adenocarcinoma Using Protein Chip Technology. Pancreatology 2008, 9:127-135. 10.1159/000178883, 19077463.
16. Hundt S, Haug U, Brenner H. Blood markers for early detection of colorectal cancer: a systematic review. Cancer Epidemiol Biomarkers Prev 2007, 16:1935-1953. 10.1158/1055-9965.EPI-06-0994, 17932341.
17. Goncalves A, Bertucci F, Birnbaum D, Borg JP. Protein profiling SELDI-TOF and breast cancer: clinical potential applications. Med Sci 2007, 23:23-26.
18. Suriano R, Lin Y, Ashok BT, Schaefer SD, Schantz SP, Geliebter J, Tiwari RK. Pilot study using SELDI-TOF-MS based proteomic profile for the identification of diagnostic biomarkers of thyroid proliferative diseases. J Proteome Res 2006, 5:856-861. 10.1021/pr050349r, 16602693.
19. Moretz WH, Gourin CG, Terris DJ, Xia ZS, Liu Z, Weinberger PM, Chin E, Adam BL. Detection of papillary thyroid carcinoma with serum protein profile analysis. Arch Otolaryngol Head Neck Surg 2008, 134:198-202. 10.1001/archoto.2007.34, 18283164.
20. Somorjai RL, Dolenko B, Baumgartner R. Class prediction and discovery using gene microarray and proteomics mass spectroscopy data: curses, caveats, cautions. Bioinformatics 2003, 19:1484-1491. 10.1093/bioinformatics/btg182, 12912828.
21. Wang XD, Wang JQ. A survey on support vector machines training and testing algorithms. Computer Engineering and Application 2004, 13:75-79.
22. Matheny ME, Resnic FS, Arora N, Ohno-Machado L. Effects of SVM parameter optimization on discrimination and calibration for post-procedural PCI mortality. J Biomed Inform 2007, 40:688-697. 10.1016/j.jbi.2007.05.008, 2170520, 17600771.
23. Fang J, Dong Y, Williams TD, Lushington GH. Feature selection in validating mass spectrometry database search results. J Bioinform Comput Biol 2008, 6:223-240. 10.1142/S0219720008003345, 18324754.
24. Wassell J. Haptoglobin: function and polymorphism. Clin lab 2000, 46:547-552.
25. Weinberg ED. The role of iron in cancer. Eur J Cancer Prev 1996, 5:19-36.
26. Reizenstein P. Iron, free radicals and cancer. Med Oncol Tumor Pharmacother 1991, 8:229-233.
27. Saldova R, Royle L, Radcliffe CM, Abd Hamid UM, Evans R, Arnold JN, Banks RE, Hutson R, Harvey DJ, Antrobus R, Petrescu SM, Dwek RA, Rudd PM. Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology 2007, 17:1344-1356. 10.1093/glycob/cwm100, 17884841.
28. Saito S, Murayama Y, Pan Y, Taima T, Fujimura T, Murayama K, Sadilek M, Egawa S, Ueno S, Ito A, Ishidoya S, Nakagawa H, Kato M, Satoh M, Endoh M, Arai Y. Haptoglobin-beta chain defined by monoclonal antibody RM2 as a novel serum marker for prostate cancer. Int J Cance 2008, 123:633-640.
29. Nakano M, Nakagawa T, Ito T, Kitada T, Hijioka T, Kasahara A, Tajiri M, Wada Y, Taniguchi N, Miyoshi E. Site-specific analysis of N-glycans on haptoglobin in sera of patients with pancreatic cancer: a novel approach for the development of tumor markers. Int J Cancer 2008, 122:2301-2309. 10.1002/ijc.23364, 18214858.
30. Huang HL, Stasyk T, Morandell S, Dieplinger H, Falkensammer G, Griesmacher A, Mogg M, Schreiber M, Feuerstein I, Huck CW, Stecher G, Bonn GK, Huber LA. Biomarker discovery in breast cancer serum using 2-D differential gel electrophoresis/MALDI-TOF/TOF and data validation by routine clinical assays. Electrophoresis 2006, 27:1641-1650. 10.1002/elps.200500857, 16550499.
31. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005, 9:59-71. 10.1111/j.1582-4934.2005.tb00337.x, 15784165.
32. Lavrentiadou SN, Hadzopoulou-Cladaras M, Kardassis D, Zannis VI. Binding specificity and modulation of the human ApoCIII promoter activity by heterodimers of ligand-dependent nuclear receptors. Biochemistry 1999, 38:964-975. 10.1021/bi981068i, 9893992.
33. Haymart MR, Repplinger DJ, Leverson GE, Elson DF, Sippel RS, Jaume JC, Chen H. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab 2008, 93:809-814. 10.1210/jc.2007-2215, 2266959, 18160464.